\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ pleural\\ effusion\\ has\\ a\\ high\\ lipid\\ content\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ \ \(0\)\
\-\ treatment\\ includes\\ oxygen\\ therapy\\,\\ medical\\ or\\ surgical\\ pleurodesis\\,\\ and\\ estrogen\\ lowering\\ therapies\\.\\ \\ most\\ commonly\\,\\ patients\\ will\\ receive\\ a\\ bilateral\\ oophorectomy\\;\\ otherwise\\,\\ depot\\ progesterone\\,\\ tamoxifen\\,\\ or\\ lhrh\\ analogs\\ may\\ be\\ used\\.\\ \\ currently\\,\\ a\\ trial\\ using\\ rapamycin\\ which\\ inhibits\\ tuberin\\ formation\\ is\\ being\\ studied\\ for\\ lam\\ and\\ tuberous\\ sclerosis\\.\\ \\ in\\ end\\-stage\\ lung\\ disease\\,\\ lung\\ transplantation\\ becomes\\ necessary\\ for\\ survival\\.\\ \\ in\\ a\\ few\\ rare\\ instances\\,\\ allograft\\ lungs\\ have\\ succumbed\\ to\\ lam\\ through\\ hematogenous\\ spread\\.\ \(0\)\
\-\ patients\\ with\\ lam\\ are\\ advised\\ not\\ to\\ fly\\ or\\ travel\\ to\\ areas\\ of\\ high\\ altitude\\ to\\ reduce\\ the\\ risk\\ of\\ pneumothoraces\\.\\ \\ they\\ are\\ discouraged\\ from\\ becoming\\ pregnant\\ as\\ this\\ can\\ lead\\ to\\ a\\ high\\ estrogen\\ state\\ that\\ accelerates\\ disease\\.\ \(0\)\
\-\ image\\ findings\\:\\ \ \(0\)\
\-\ cxr\\:\\ \\ this\\ patient\\ has\\ a\\ large\\,\\ dense\\ pleural\\ effusion\\ in\\ right\\ lower\\ lobe\\ and\\ a\\ bilaterally\\ diffuse\\ mild\\ linear\\ reticular\\ pattern\\.\ \(0\)\
\-\ ct\\:\\ \\ this\\ patient\\ has\\ cystic\\ air\\ pockets\\ throughout\\ all\\ lung\\ fields\\ and\\ a\\ dense\\ pleural\\ effusion\\ in\\ the\\ right\\ lower\\ lobe\\.\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\,\\ tuberous\\ sclerosis\\,\\ eosinophilic\\ granuloma\\ \\(langerhans\\ histiocytosis\\)\\,\\ emphysema\\,\\ cystic\\ fibrosis\\,\\ bronchiectasis\\,\\ idiopathic\\ pulmonary\\ fibrosis\\,\\ neurofibromatosis\\ \\(types\\ 1\\ and\\ 2\\)\\,\\ metastatic\\ leiomyosarcoma\\,\\ metastatic\\ leiomyoma\\,\\ metastatic\\ endometrial\\ stromal\\ tumor\\,\\ diffuse\\ pulmonary\\ lymphangiomatosis\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ 48\\ year\\-old\\ female\\ with\\ history\\ of\\ lung\\ disease\\ with\\ recurrent\\ pneumothoraces\ \(1\)\
\-\ though\\ not\\ given\\ in\\ this\\ case\\,\\ symptoms\\ of\\ dyspnea\\ and\\ cough\\ are\\ most\\ common\\.\\ \\ others\\ include\\ hemoptysis\\ and\\ chest\\ pain\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ this\\ rare\\ disease\\ occurs\\ in\\ women\\ of\\ childbearing\\ age\\,\\ mostly\\ caucasians\\.\\ \\ it\\ is\\ caused\\ by\\ proliferating\\ smooth\\ muscle\\ in\\ the\\ interstitium\\.\\ \\ although\\ not\\ cancerous\\,\\ it\\ can\\ metastasize\\ to\\ other\\ parts\\ of\\ the\\ body\\.\\ \\ it\\ is\\ estimated\\ that\\ there\\ may\\ be\\ a\\ 1\\,000\\ women\\ with\\ this\\ disease\\ in\\ the\\ united\\ states\\.\\ \\ the\\ nih\\ follows\\ the\\,\\ approximately\\,\\ 350\\ known\\ patients\\.\\ \\ many\\ patients\\ are\\ misdiagnosed\\ with\\ asthma\\ or\\ copd\\.\ \(0\)\
\-\ though\\ idiopathic\\,\\ it\\ is\\ closely\\ related\\ to\\ tuberous\\ sclerosis\\.\\ \\ in\\ fact\\,\\ some\\ believe\\ that\\ it\\ may\\ possibly\\ be\\ an\\ attenuated\\ or\\ mosaic\\ presentation\\ of\\ tuberous\\ sclerosis\\.\\ \\ unlike\\ tuberous\\ sclerosis\\,\\ there\\ are\\ no\\ brain\\ or\\ skin\\ lesions\\.\\ \\ the\\ progression\\ of\\ disease\\ has\\ been\\ clinically\\ linked\\ to\\ estrogen\\ levels\\.\ \(0\)\
\-\ complications\\ include\\ spontaneous\\ pneumothraces\\ \\(50\\%\\)\\,\\ which\\ may\\ be\\ bilateral\\ or\\ recurrent\\,\\ renal\\ angiomyolipomas\\ \\(hamartomas\\,\\ 50\\%\\)\\,\\ hematothorax\\,\\ chylothorax\\,\\ chyloperitoneum\\,\\ chylouria\\,\\ and\\ chylopericardium\\.\ \(0\)\
\-\ classically\\,\\ lam\\ entails\\ a\\ 8\\-10\\ year\\ survival\\ rate\\,\\ but\\ patients\\ may\\ now\\ live\\ for\\ 20\\-50\\ more\\ years\\ with\\ treatment\\.\ \(0\)\
\-\ \\â\\€\\¢discussion\\ with\\ dr\\.\\ avila\\ of\\ the\\ nih\\.\ \(0\)\
\-\ \\â\\€\\¢kazuhiro\\ matsui\\,\\ et\\ al\\,\\ prognostic\\ significance\\ of\\ pulmonary\\ lymphangioleiomyomatosis\\ histologic\\ score\\,\\ am\\ j\\ surg\\ pathol\\ 2001\\;25\\:479\\-484\\.\ \(0\)\
\-\ \\â\\€\\¢kumasaka\\ t\\,\\ etal\\,\\ lymphangiogenesis\\ in\\ lymphangioleiomyomatosis\\:\\ its\\ implication\\ in\\ the\\ progression\\ of\\ lymphangioleiomyomatosis\\,\\ am\\ j\\ surg\\ pathol\\.\\ 2004\\ aug\\;28\\(8\\)\\:1007\\-1016\\.\\ \ \(0\)\
\-\ \\â\\€\\¢uptodate\\ online\\:\\ \\ pulmonary\\ lymphangioleiomyomatosis\ \(0\)\
\-\ \\â\\€\\¢http\\:\\/\\/lam\\.uc\\.edu\\/html\\/disease\\.html\\ \\(lam\\ foundation\\)\\.\ \(0\)\
\-\ \\â\\€\\¢http\\:\\/\\/www\\.lungusa\\.org\\/site\\/pp\\.asp\\?c\\=dvluk9o0e\\&b\\=36\\ \\(am\\.\\ lung\\ as\\.\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lam\\:\\ 0\\.3502651952388883\ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.29430199570079196\ \(0\)\
\-\ tuberous\\:\\ 0\\.19628549417152924\ \(0\)\
\-\ estrogen\\:\\ 0\\.14715099785039598\ \(0\)\
\-\ pulmonary\\:\\ 0\\.14397364161854212\ \(0\)\
\-\ sclerosis\\:\\ 0\\.1401989807764915\ \(0\)\
\-\ in\\:\\ 0\\.1273099230449387\ \(0\)\
\-\ lung\\:\\ 0\\.11973503739945746\ \(0\)\
\-\ disease\\:\\ 0\\.11567217515299238\ \(0\)\
\-\ am\\:\\ 0\\.11148407357222195\ \(0\)\
\-\ patients\\:\\ 0\\.11072863227835605\ \(0\)\
\-\ or\\:\\ 0\\.10955882563616036\ \(0\)\
\-\ pneumothoraces\\:\\ 0\\.10369697113183401\ \(0\)\
\-\ pathol\\:\\ 0\\.1023814820534035\ \(0\)\
\-\ it\\:\\ 0\\.10075542917886773\ \(0\)\
\-\ may\\:\\ 0\\.09905195043196717\ \(0\)\
\-\ this\\:\\ 0\\.09468891452474411\ \(0\)\
\-\ include\\:\\ 0\\.09369048627943617\ \(0\)\
\-\ pleural\\:\\ 0\\.0889041598111299\ \(0\)\
\-\ effusion\\:\\ 0\\.08769780212079925\ \(0\)\
\-\ of\\:\\ 0\\.08474203122422222\ \(0\)\
\-\ surg\\:\\ 0\\.083889663837707\ \(0\)\
\-\ 50\\:\\ 0\\.08247741444196119\ \(0\)\
\-\ and\\:\\ 0\\.0813457486800872\ \(0\)\
\-\ to\\:\\ 0\\.07873208719778232\ \(0\)\
\-\ the\\:\\ 0\\.0785501383198499\ \(0\)\
\-\ nih\\:\\ 0\\.0785141976686117\ \(0\)\
\-\ survival\\:\\ 0\\.07683915222996236\ \(0\)\
\-\ are\\:\\ 0\\.07468870278807382\ \(0\)\
\-\ age\\:\\ 0\\.07414375823131905\ \(0\)\
\-\ progression\\:\\ 0\\.07219509895696442\ \(0\)\
\-\ has\\:\\ 0\\.07192561187679038\ \(0\)\
\-\ women\\:\\ 0\\.07085402657442817\ \(0\)\
\-\ dense\\:\\ 0\\.0693998208649202\ \(0\)\
\-\ discussion\\:\\ 0\\.06894724954571933\ \(0\)\
\-\ though\\:\\ 0\\.06840163745315678\ \(0\)\
\-\ high\\:\\ 0\\.06711976700316714\ \(0\)\
\-\ idiopathic\\:\\ 0\\.06659879305872772\ \(0\)\
\-\ fibrosis\\:\\ 0\\.06595671502863946\ \(0\)\
\-\ metastatic\\:\\ 0\\.06477142589991751\ \(0\)\
\-\ be\\:\\ 0\\.06387742237514331\ \(0\)\
\-\ recurrent\\:\\ 0\\.06313010391834126\ \(0\)\
\-\ depot\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ lhrh\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ rapamycin\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ pneumothraces\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ hematothorax\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ chylouria\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ chylopericardium\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ avila\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ matsui\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ etal\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ lymphangiogenesis\\:\\ 0\\.06295536838035386\ \(0\)\
\-\ can\\:\\ 0\\.06197464461124243\ \(0\)\
\-\ tuberin\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ discouraged\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ accelerates\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ lymphangiomatosis\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ caucasians\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ proliferating\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ chyloperitoneum\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ implication\\:\\ 0\\.06015721543123552\ \(0\)\
\-\ rare\\:\\ 0\\.05943606791733184\ \(0\)\
\-\ mosaic\\:\\ 0\\.05817189431890767\ \(0\)\
\-\ entails\\:\\ 0\\.05817189431890767\ \(0\)\
\-\ analogs\\:\\ 0\\.0566319596273632\ \(0\)\
\-\ altitude\\:\\ 0\\.0566319596273632\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.0566319596273632\ \(0\)\
\-\ treatment\\:\\ 0\\.056256848207161196\ \(0\)\
\-\ pleurodesis\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ succumbed\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ pockets\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ cancerous\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ chylothorax\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ foundation\\:\\ 0\\.05537374136978933\ \(0\)\
\-\ lowering\\:\\ 0\\.05430993299086422\ \(0\)\
\-\ fly\\:\\ 0\\.05430993299086422\ \(0\)\
\-\ with\\:\\ 0\\.053958968361254585\ \(0\)\
\-\ inhibits\\:\\ 0\\.053388420257461495\ \(0\)\
\-\ studied\\:\\ 0\\.053388420257461495\ \(0\)\
\-\ allograft\\:\\ 0\\.053388420257461495\ \(0\)\
\-\ childbearing\\:\\ 0\\.053388420257461495\ \(0\)\
\-\ tamoxifen\\:\\ 0\\.05184848556591701\ \(0\)\
\-\ that\\:\\ 0\\.05125056258804814\ \(0\)\
\-\ progesterone\\:\\ 0\\.05119074102670175\ \(0\)\
\-\ 350\\:\\ 0\\.05119074102670175\ \(0\)\
\-\ online\\:\\ 0\\.05119074102670175\ \(0\)\
\-\ aug\\:\\ 0\\.050590267308343144\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.04952645892941804\ \(0\)\
\-\ instances\\:\\ 0\\.04952645892941804\ \(0\)\
\-\ diffuse\\:\\ 0\\.04937515177756876\ \(0\)\
\-\ interstitium\\:\\ 0\\.04905033261679866\ \(0\)\
\-\ believe\\:\\ 0\\.04905033261679866\ \(0\)\
\-\ live\\:\\ 0\\.04905033261679866\ \(0\)\
\-\ angiomyolipomas\\:\\ 0\\.048604946196015304\ \(0\)\
\-\ hamartomas\\:\\ 0\\.048604946196015304\ \(0\)\
\-\ metastasize\\:\\ 0\\.04818656996355392\ \(0\)\
\-\ attenuated\\:\\ 0\\.04818656996355392\ \(0\)\
\-\ becoming\\:\\ 0\\.0477921143592248\ \(0\)\
\-\ for\\:\\ 0\\.04772655776939741\ \(0\)\
\-\ parts\\:\\ 0\\.047418991366339064\ \(0\)\
\-\ cystic\\:\\ 0\\.04741803025309589\ \(0\)\
\-\ not\\:\\ 0\\.04662269910258691\ \(0\)\
\-\ travel\\:\\ 0\\.04640726696525556\ \(0\)\
\-\ therapies\\:\\ 0\\.04610050115965656\ \(0\)\
\-\ prognostic\\:\\ 0\\.04610050115965656\ \(0\)\
\-\ transplantation\\:\\ 0\\.04580679324689696\ \(0\)\
\-\ dr\\:\\ 0\\.04580679324689696\ \(0\)\
\-\ lipid\\:\\ 0\\.04552507681292634\ \(0\)\
\-\ lobe\\:\\ 0\\.04549918441731065\ \(0\)\
\-\ reticular\\:\\ 0\\.044993961410106455\ \(0\)\
\-\ hematogenous\\:\\ 0\\.044742984867971854\ \(0\)\
\-\ score\\:\\ 0\\.044742984867971854\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.04450081636060878\ \(0\)\
\-\ significance\\:\\ 0\\.04426685855535248\ \(0\)\
\-\ histologic\\:\\ 0\\.044040572895752035\ \(0\)\
\-\ trial\\:\\ 0\\.04382147213456912\ \(0\)\
\-\ advised\\:\\ 0\\.04382147213456912\ \(0\)\
\-\ unlike\\:\\ 0\\.04382147213456912\ \(0\)\
\-\ linked\\:\\ 0\\.04340309590210774\ \(0\)\
\-\ is\\:\\ 0\\.04312297279687228\ \(0\)\
\-\ stromal\\:\\ 0\\.043008640297778615\ \(0\)\
\-\ united\\:\\ 0\\.043008640297778615\ \(0\)\
\-\ bilateral\\:\\ 0\\.04231386141987112\ \(0\)\
\-\ closely\\:\\ 0\\.04228153744302464\ \(0\)\
\-\ copd\\:\\ 0\\.0419448319188535\ \(0\)\
\-\ receive\\:\\ 0\\.04146870560623413\ \(0\)\
\-\ others\\:\\ 0\\.04146870560623413\ \(0\)\
\-\ pregnant\\:\\ 0\\.04131702709821038\ \(0\)\
\-\ langerhans\\:\\ 0\\.04131702709821038\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.04116861074780191\ \(0\)\
\-\ mostly\\:\\ 0\\.04116861074780191\ \(0\)\
\-\ classically\\:\\ 0\\.04116861074780191\ \(0\)\
\-\ most\\:\\ 0\\.04097488424623655\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.040881023539928396\ \(0\)\
\-\ estimated\\:\\ 0\\.040881023539928396\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.04074160275148015\ \(0\)\
\-\ oxygen\\:\\ 0\\.04047093691123453\ \(0\)\
\-\ lower\\:\\ 0\\.04023249868859791\ \(0\)\
\-\ endometrial\\:\\ 0\\.04021048734866027\ \(0\)\
\-\ reduce\\:\\ 0\\.04008385821226489\ \(0\)\
\-\ state\\:\\ 0\\.03971734229916259\ \(0\)\
\-\ case\\:\\ 0\\.039554455256049274\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.03948338449390629\ \(0\)\
\-\ asthma\\:\\ 0\\.03925709883430585\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.039037998073122936\ \(0\)\
\-\ content\\:\\ 0\\.03893100221969004\ \(0\)\
\-\ findings\\:\\ 0\\.0388577483064261\ \(0\)\
\-\ fields\\:\\ 0\\.0387218621448262\ \(0\)\
\-\ emphysema\\:\\ 0\\.038619621840661554\ \(0\)\
\-\ follows\\:\\ 0\\.038518874149092025\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.03832168661119601\ \(0\)\
\-\ gestational\\:\\ 0\\.03822516623633243\ \(0\)\
\-\ fact\\:\\ 0\\.03776183157576592\ \(0\)\
\-\ becomes\\:\\ 0\\.03767278396211619\ \(0\)\
\-\ 2001\\:\\ 0\\.03716135785740732\ \(0\)\
\-\ 2004\\:\\ 0\\.037079687149117066\ \(0\)\
\-\ possibly\\:\\ 0\\.036998971675696726\ \(0\)\
\-\ types\\:\\ 0\\.036608975583191074\ \(0\)\
\-\ which\\:\\ 0\\.035800544688401645\ \(0\)\
\-\ granuloma\\:\\ 0\\.03562142316586284\ \(0\)\
\-\ spread\\:\\ 0\\.035363408281142955\ \(0\)\
\-\ lead\\:\\ 0\\.03505389029432835\ \(0\)\
\-\ dyspnea\\:\\ 0\\.034642639611603444\ \(0\)\
\-\ states\\:\\ 0\\.034585840160871385\ \(0\)\
\-\ spontaneous\\:\\ 0\\.03425452401167675\ \(0\)\
\-\ 48\\:\\ 0\\.03409464595076668\ \(0\)\
\-\ few\\:\\ 0\\.03339393354617192\ \(0\)\
\-\ necessary\\:\\ 0\\.032933690081315185\ \(0\)\
\-\ clinically\\:\\ 0\\.03271458932013226\ \(0\)\
\-\ 28\\:\\ 0\\.03267159170872073\ \(0\)\
\-\ smooth\\:\\ 0\\.032502231201700364\ \(0\)\
\-\ using\\:\\ 0\\.032377883795961133\ \(0\)\
\-\ linear\\:\\ 0\\.03171267457856358\ \(0\)\
\-\ as\\:\\ 0\\.03162972218012484\ \(0\)\
\-\ caused\\:\\ 0\\.03156505195917063\ \(0\)\
\-\ cxr\\:\\ 0\\.03149240819043647\ \(0\)\
\-\ references\\:\\ 0\\.03138485649194617\ \(0\)\
\-\ there\\:\\ 0\\.03132749929979221\ \(0\)\
\-\ al\\:\\ 0\\.031278955268431774\ \(0\)\
\-\ formation\\:\\ 0\\.031209246652428184\ \(0\)\
\-\ levels\\:\\ 0\\.031209246652428184\ \(0\)\
\-\ occurs\\:\\ 0\\.031037994830097018\ \(0\)\
\-\ many\\:\\ 0\\.031037994830097018\ \(0\)\
\-\ et\\:\\ 0\\.030837949104416652\ \(0\)\
\-\ includes\\:\\ 0\\.03061166344481621\ \(0\)\
\-\ currently\\:\\ 0\\.030240214459047638\ \(0\)\
\-\ complications\\:\\ 0\\.030150394176270225\ \(0\)\
\-\ history\\:\\ 0\\.030080451515452106\ \(0\)\
\-\ related\\:\\ 0\\.029916436371013922\ \(0\)\
\-\ rate\\:\\ 0\\.029830707388977393\ \(0\)\
\-\ used\\:\\ 0\\.029471049950230567\ \(0\)\
\-\ pattern\\:\\ 0\\.02939064794206461\ \(0\)\
\-\ cough\\:\\ 0\\.02939064794206461\ \(0\)\
\-\ skin\\:\\ 0\\.029284881974453135\ \(0\)\
\-\ commonly\\:\\ 0\\.029129211592571293\ \(0\)\
\-\ its\\:\\ 0\\.029129211592571293\ \(0\)\
\-\ lungs\\:\\ 0\\.029052673717769182\ \(0\)\
\-\ throughout\\:\\ 0\\.028951926026199656\ \(0\)\
\-\ laboratory\\:\\ 0\\.02858670354282782\ \(0\)\
\-\ risk\\:\\ 0\\.028127990254098564\ \(0\)\
\-\ they\\:\\ 0\\.028127990254098564\ \(0\)\
\-\ otherwise\\:\\ 0\\.028061739239943616\ \(0\)\
\-\ muscle\\:\\ 0\\.02795271494551048\ \(0\)\
\-\ being\\:\\ 0\\.027432023552804358\ \(0\)\
\-\ presentation\\:\\ 0\\.027099140290878083\ \(0\)\
\-\ given\\:\\ 0\\.027080050114647494\ \(0\)\
\-\ now\\:\\ 0\\.027023094405058054\ \(0\)\
\-\ although\\:\\ 0\\.026799858952935633\ \(0\)\
\-\ areas\\:\\ 0\\.026727023508434703\ \(0\)\
\-\ bilaterally\\:\\ 0\\.026254520768650834\ \(0\)\
\-\ right\\:\\ 0\\.026103149609792264\ \(0\)\
\-\ body\\:\\ 0\\.025908156608464065\ \(0\)\
\-\ air\\:\\ 0\\.025749138183293677\ \(0\)\
\-\ patient\\:\\ 0\\.02560779673087018\ \(0\)\
\-\ differential\\:\\ 0\\.02557834873035109\ \(0\)\
\-\ known\\:\\ 0\\.02548694217143598\ \(0\)\
\-\ will\\:\\ 0\\.025337237943015633\ \(0\)\
\-\ image\\:\\ 0\\.025176229500240878\ \(0\)\
\-\ approximately\\:\\ 0\\.025118599985327287\ \(0\)\
\-\ medical\\:\\ 0\\.025018892037979017\ \(0\)\
\-\ days\\:\\ 0\\.024920604191135825\ \(0\)\
\-\ some\\:\\ 0\\.02476892568311207\ \(0\)\
\-\ brain\\:\\ 0\\.0245408804380083\ \(0\)\
\-\ renal\\:\\ 0\\.02451454035142598\ \(0\)\
\-\ year\\:\\ 0\\.02426386981815024\ \(0\)\
\-\ years\\:\\ 0\\.02413104756799905\ \(0\)\
\-\ weeks\\:\\ 0\\.02359302761802325\ \(0\)\
\-\ through\\:\\ 0\\.023433851994317377\ \(0\)\
\-\ all\\:\\ 0\\.023433851994317377\ \(0\)\
\-\ been\\:\\ 0\\.02293528307880799\ \(0\)\
\-\ months\\:\\ 0\\.0229144022934173\ \(0\)\
\-\ therapy\\:\\ 0\\.022618522927788504\ \(0\)\
\-\ lesions\\:\\ 0\\.02260854303551178\ \(0\)\
\-\ common\\:\\ 0\\.02232523115723705\ \(0\)\
\-\ mild\\:\\ 0\\.0223156662294319\ \(0\)\
\-\ these\\:\\ 0\\.02223017325889679\ \(0\)\
\-\ more\\:\\ 0\\.02161633826955579\ \(0\)\
\-\ symptoms\\:\\ 0\\.021539038334095133\ \(0\)\
\-\ physical\\:\\ 0\\.021345340238677037\ \(0\)\
\-\ chest\\:\\ 0\\.020779555918315942\ \(0\)\
\-\ tumor\\:\\ 0\\.020590886587043816\ \(0\)\
\-\ other\\:\\ 0\\.020443579087911043\ \(0\)\
\-\ diagnosis\\:\\ 0\\.020407238328279537\ \(0\)\
\-\ exam\\:\\ 0\\.019817041744071447\ \(0\)\
\-\ large\\:\\ 0\\.0197244969469738\ \(0\)\
\-\ have\\:\\ 0\\.019665652584040714\ \(0\)\
\-\ but\\:\\ 0\\.01946672302856091\ \(0\)\
\-\ surgical\\:\\ 0\\.01913333164461078\ \(0\)\
\-\ female\\:\\ 0\\.01899608097371017\ \(0\)\
\-\ by\\:\\ 0\\.016717236590816333\ \(0\)\
\-\ from\\:\\ 0\\.015634646415169727\ \(0\)\
\-\ an\\:\\ 0\\.015053561209811243\ \(0\)\
\-\ ct\\:\\ 0\\.014987140155141158\ \(0\)\
\-\ pain\\:\\ 0\\.014086729804079892\ \(0\)\
\-\ no\\:\\ 0\\.012801490026793769\ \(0\)\
